AbbVie and iSTAR Medical form strategic alliance for glaucoma treatment

AbbVie and iSTAR Medical announced a strategic transaction to develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical device. The deal includes a $60 million upfront payment to iSTAR Medical, which will continue development and commercialization up to completion of the U.S. PMA study.

“Deal terms include a $60M upfront payment to iSTAR Medical”news.abbvie.com

• 1 source
• news.abbvie.comAbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma - Jul 20, 2022Jul 20, 2022

Summarized from public sources; check the original articles before acting on it.